A blinded randomised multicentre study to evaluate fixed dose single administration filgrastim-SD/01 vs daily filgrastim as an adjuvant to chemotherapy Stage II or III/IV breast cancer
Not Applicable
Completed
- Conditions
- Breast CancerCancer
- Registration Number
- ISRCTN19151731
- Lead Sponsor
- Amgen Limited (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. 18 years of age or older
2. Can be chemotherapy naive and/or have no more than one previous regimen of chemotherapy for metastatic disease
3. Blood results within acceptable range
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration